Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Patients Reported Improvement in Quality of “OFF” time, Severity of Non-Motor Fluctuations, and Medication Satisfaction in the OPTI-ON Study
Movement Disorders
S32 - Movement Disorders: Trials (4:42 PM-4:54 PM)
007
Opicapone is an oral, once-daily, selective catechol-O-methyltransferase (COMT) inhibitor used as adjunctive treatment to carbidopa/levodopa (CD/LD) in patients with Parkinson’s disease (PD) experiencing “OFF” episodes. The aim of the OPTI-ON study was to evaluate “real-world” patient characteristics, treatment patterns, and safety/tolerability of opicapone use in the US.
To describe patient-reported outcomes (PROs) from the Opicapone Treatment Initiation Open-Label Study (OPTI-ON).
OPTI-ON was a prospective, open-label, single-arm, multicenter, observational, longitudinal (6-month) study of patients with PD experiencing “OFF” episodes who were prescribed opicapone adjunctive to CD/LD. PROs including the Patient Global Impression of Severity in the “OFF” state (PGI-S OFF), Patient Global Impression of Change (PGI-C), Non-Motor Fluctuations PGI-S (NMFs PGI-S), and Medication Satisfaction Questionnaire (MSQ) were obtained at baseline (BL) and throughout follow-up.
Overall, 164 patients completed the study. On the PGI-S OFF, more patients rated their “OFF” time symptom severity as none or very mild at 3 months (21.2%) and 6 months (20.4%) compared to BL (10.3%). For the PGI-C, 29.8% and 23.5% of patients were much or very much improved at months 3 and 6, respectively. On the NMFs PGI-S, fewer patients scored markedly to most extremely affected with NMFs at 6 months (3.2%) compared to BL (11.9%). On the MSQ, 42.3% of patients were very or extremely satisfied with their opicapone treatment at 6 months versus 14.2% with their treatment regimen at BL.
After 6 months of opicapone treatment, patients reported improvement on the PGI-S OFF and PGI-C, reduced NMF severity on the NMFs PGI-S, and increased satisfaction on the MSQ. In addition to decreasing the duration of “OFF” episodes as shown in Phase 3 clinical studies, these results suggest once-daily opicapone may improve the quality of “OFF” time, more effectively manage motor fluctuations and NMFs in PD, and increase patients’ satisfaction with their PD treatment regimen.
Authors/Disclosures
Peter A. LeWitt, MD (Henry Ford Hospital - Franklin Pointe)
PRESENTER
Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acorda Therapeutics. Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal Pharmaceuticals. Dr. LeWitt has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for US WorldMeds LLC. Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kyowa Kirin Inc. Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe-NeuroDerm Neuropharma. Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bukwang Pharmaceuticals. Dr. LeWitt has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. Dr. LeWitt has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for CLINICAL NEUROPHARMACOLOGY.
Olga Klepitskaya, MD, FAAN (Neurocrine Biosciences, Inc) Dr. Klepitskaya has received personal compensation for serving as an employee of Neurocrine Biosciences, Inc.
Michael Serbin Michael Serbin has received personal compensation for serving as an employee of Neurocrine Biosciences, Inc.
Eric Jen (Neurocrine Biosciences, Inc.) Eric Jen has received personal compensation for serving as an employee of Neurocrine Biosciences, Inc.
Stacy Rattana Stacy Rattana has received personal compensation for serving as an employee of Worldwide Clinical Trials.
Jeffrey Trotter Jeffrey Trotter has received personal compensation for serving as an employee of Worldwide Clinical Trials.
Grace Lin Liang, MD Dr. Liang has received personal compensation for serving as an employee of Neurocrine Biosciences. Dr. Liang has stock in Neurocrine Biosciences.